National Cancer Institute; Notice of Closed Meeting, 17614 [2021-06890]
Download as PDF
<![CDATA[
17614
Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices
jbell on DSKJLSW7X2PROD with NOTICES
(3) Two oral public comment
sessions: One session will be open to
any newborn screening related topic.
The other public comment period will
specifically address the Committee’s
review of the evidence review process
(e.g., nomination form, consumerfriendly guidance materials, review of
conditions on the RUSP). Please note, if
you wish to register to submit oral
public comments on the review of the
Committee’s evidence review process
we request that you also submit a
written version of your remarks;
(4) Committee discussion of
Continuity of Operations Planning and
COVID–19; and,
(5) Newborn screening data sources.
The agenda for this meeting does not
include any plans for recommending a
condition for inclusion in the RUSP.
However, as noted in the agenda items,
the Committee may hold a vote on
whether or not to recommend a
nominated condition (MPS II) to full
evidence review, which may lead to
such a recommendation at a future time.
Agenda items are subject to change as
priorities dictate. Information about the
ACHDNC, including a roster of members
and past meeting summaries, is also
available on the ACHDNC website
previously listed.
As noted above, members of the
public will have the opportunity to
provide comments. Public participants
providing general oral comments may
submit written statements in advance of
the scheduled meeting. We specifically
request that public participants
providing oral comment on the review
of the Committee’s evidence review
process also submit a written version of
their remarks. Oral comments will be
honored in the order they are requested
and may be limited as time allows.
Requests to provide a written statement
or make oral comments to the ACHDNC
must be submitted via the registration
website by 10:00 a.m. ET on Monday,
May 10, 2021.
Individuals who need special
assistance or another reasonable
accommodation should notify Alaina
Harris at the address and phone number
listed above at least 10 business days
prior to the meeting.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2021–06940 Filed 4–2–21; 8:45 am]
BILLING CODE 4165–15–P
VerDate Sep<11>2014
17:23 Apr 02, 2021
Jkt 253001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; FEB2021
Cycle 37 NExT SEP Committee Meeting.
Date: April 21, 2021.
Time: 9:00 a.m. to 3:00 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Room 3A44,
Bethesda, Maryland 20892 (WebEx Meeting).
Contact Persons: Barbara Mroczkowski,
Ph.D. Executive Secretary, Discovery
Experimental Therapeutics Program,
National Cancer Institute, NIH, 31 Center
Drive, Room 3A44, Bethesda, MD 20817,
(301) 496–4291, mroczkoskib@mail.nih.gov.
Toby Hecht, Ph.D., Executive Secretary,
Development Experimental Therapeutics
Program, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 3W110,
Rockville, MD 20850, (240) 276–5683,
toby.hecht2@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
Dated: March 30, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–06890 Filed 4–2–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
0361.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: 2022 National Survey
on Drug Use and Health (OMB No.
0930–0110)
The National Survey on Drug Use and
Health (NSDUH) is a survey of the U.S.
civilian, non-institutionalized
population aged 12 years old or older.
The data are used to determine the
prevalence of use of tobacco products,
alcohol, illicit substances, and illicit use
of prescription drugs. The results are
used by SAMHSA, the Office of
National Drug Control Policy (ONDCP),
federal government agencies, and other
organizations and researchers to
establish policy, direct program
activities, and better allocate resources.
As certain parts of the United States
reduce COVID–19 restrictions, NSDUH
in-person data collection will proceed
where possible. However, to ensure
E:\FR\FM\05APN1.SGM
05APN1
]]>Agencies
[Federal Register Volume 86, Number 63 (Monday, April 5, 2021)]
[Notices]
[Page 17614]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06890]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The purpose of this meeting is to evaluate requests
for preclinical development resources for potential new therapeutics
for the treatment of cancer. The outcome of the evaluation will provide
information to internal NCI committees that will decide whether NCI
should support requests and make available contract resources for
development of the potential therapeutic to improve the treatment of
various forms of cancer. The research proposals and the discussions
could disclose confidential trade secrets or commercial property such
as patentable material, and personal information concerning individuals
associated with the proposed research projects, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; FEB2021 Cycle 37 NExT SEP Committee Meeting.
Date: April 21, 2021.
Time: 9:00 a.m. to 3:00 p.m.
Agenda: To evaluate the NCI Experimental Therapeutics Program
Portfolio.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, Room 3A44, Bethesda, Maryland 20892 (WebEx Meeting).
Contact Persons: Barbara Mroczkowski, Ph.D. Executive Secretary,
Discovery Experimental Therapeutics Program, National Cancer
Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20817,
(301) 496-4291, [email protected].
Toby Hecht, Ph.D., Executive Secretary, Development Experimental
Therapeutics Program, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 3W110, Rockville, MD 20850, (240) 276-5683,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: March 30, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-06890 Filed 4-2-21; 8:45 am]
BILLING CODE 4140-01-P
